Virtual Library

Start Your Search

Ki Hyeong Lee



Author of

  • +

    P2.12 - Small Cell Lung Cancer/NET (Not CME Accredited Session) (ID 961)

    • Event: WCLC 2018
    • Type: Poster Viewing in the Exhibit Hall
    • Track:
    • Presentations: 1
    • Moderators:
    • Coordinates: 9/25/2018, 16:45 - 18:00, Exhibit Hall
    • +

      P2.12-01 - Efficacy of Belotecan as Second-Line Treatment for Recurrent Small Cell Lung Cancer: A Phase IIb Randomized Multicenter Study (ID 13658)

      16:45 - 18:00  |  Author(s): Ki Hyeong Lee

      • Abstract
      • Slides

      Background

      Topotecan is recommended as second-line treatment for patients with progressive/recurrent extensive-stage small cell lung cancer (ES-SCLC) after platinum-based combination chemotherapy. Although some topotecan-treated patients may have at least an objective response (OR), response duration is often short. Belotecan, a camptothecin derivative topoisomerase I inhibitor, has shown promising antitumor activity and modest toxicities against advanced SCLC and ovarian cancers. We report efficacy data from a phase IIb randomized multicenter study of belotecan as second-line treatment for progressive/recurrent limited-disease (LD)- or ES-SCLC.

      a9ded1e5ce5d75814730bb4caaf49419 Method

      This study, conducted from March 2010 to March 2018, was designed to prove the non-inferiority of belotecan to topotecan. Patients were randomized (1:1) to belotecan 0.5 mg/m2 or topotecan 1.5 mg/m2 intravenously for 5 consecutive days every 3 weeks for 6 cycles or until disease progression. The primary endpoint was objective response rate (ORR; complete response [CR] or partial response [PR]) based on RECIST criteria; secondary endpoints were progression-free survival (PFS), overall survival (OS).

      4c3880bb027f159e801041b1021e88e8 Result

      Overall, 148 patients (belotecan, n=72; topotecan, n=76) were eligible in the full analysis set (FAS; patients who received at least one dose); 113 patients (belotecan, n=62; topotecan; n=51) were evaluable in the per-protocol set (PPS; patients who completed the study protocol). Clinical characteristics were well balanced between the two treatment arms. In the FAS, ORR was 33.33% (belotecan) and 21.05% (topotecan), respectively (95% CI: −0.0195 to 0.2651, p=0.0927). One belotecan recipient had a CR. Median OS was 396 days (belotecan) and 247 days (topotecan), respectively (p=0.0178); median PFS was 144 and 115 days, respectively (p=0.9608). Similar efficacy outcomes were observed in the PPS.

      wclc_2018_abstract_efficacy only_final_4 may 2018.jpg

      8eea62084ca7e541d918e823422bd82e Conclusion

      Our data met the hypothesis that the antitumor efficacy of belotecan is non-inferior to that of topotecan as second-line treatment for patients with progressive/recurrent LD- or ES-SCLC. Belotecan was also associated with significantly longer OS. (ClinicalTrials.gov. ID: NCT01497873; https://clinicaltrials.gov/ct2/show/NCT01497873)

      6f8b794f3246b0c1e1780bb4d4d5dc53

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.